Hawley-Harshbarger Bill Targets FDA Approval of Abortion Drug Mifepristone
Event summary
- Sen. Josh Hawley and Rep. Harshbarger introduced a bill to revoke FDA approval of mifepristone, an abortion drug.
- The bill aims to remove mifepristone from the market and allow lawsuits against the FDA for alleged negligence.
- Family Research Council (FRC) supports the bill, citing safety concerns and increased abortion rates post-Roe v. Wade.
- FRC claims over 10% of women using mifepristone experience serious complications.
The big picture
The bill reflects ongoing tensions between federal and state regulations on abortion post-Roe v. Wade. It also highlights the growing scrutiny over FDA's approval processes for controversial drugs. The legislative push could reshape access to abortion medications and influence future regulatory oversight of pharmaceuticals with significant societal impact.
What we're watching
- Legislative Momentum
- Whether the Hawley-Harshbarger bill gains traction in Congress amid polarized abortion debates.
- Regulatory Response
- How the FDA will react to the bill and potential legal challenges to its approval process.
- Market Impact
- The potential disruption to the abortion drug market if mifepristone is removed from circulation.
Related topics